BUZZ-中期癌症研究中期结果公布后,Gritstone 生物公司股价下跌

Reuters
Oct 01, 2024

((自动化翻译由路透提供,请见免责声明 ))

10月1日 - ** 药物开发商 Gritstone bio 股价盘前下跌 16.2% 至 49 美分

** 该公司周一宣布, (link) 为结肠直肠癌患者测试实验性疫苗的中期研究的中期结果

** GRTS称,与标准治疗相比,疫苗使疾病进展或死亡的相对风险降低了21%。

** 称临床获益最明显的是疾病负担较轻的患者,并补充说需要继续随访以全面评估治疗效果

** 该公司曾在疾病进展较快的高危患者中测试疫苗

** GRTS 还表示已聘请 Raymond James 担任财务顾问,以探索和审查潜在的价值最大化战略

** 截至最后收盘,股价累计下跌 71.6

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10